These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. Amsterdam JD, Shults J. J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727 [Abstract] [Full Text] [Related]
3. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression? Castrogiovanni P, Blardi P, De Lalla A, Dell'Erba A, Auteri A. Psychopharmacol Bull; 2003 Apr; 37(2):102-8. PubMed ID: 14566218 [Abstract] [Full Text] [Related]
4. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert JE, Franznick DA, Hollander SB, Fava M. J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591 [Abstract] [Full Text] [Related]
5. Urinary 3-methoxy-4-hydroxyphenylglycol and the depression-type score as predictors of differential responses to antidepressants. Mooney JJ, Schatzberg AF, Cole JO, Samson JA, Waternaux C, Gerson B, Pappalardo KM, Schildkraut JJ. J Clin Psychopharmacol; 1991 Dec; 11(6):339-43. PubMed ID: 1770151 [Abstract] [Full Text] [Related]
6. Tranylcypromine: patterns and predictors of response. White K, White J. J Clin Psychiatry; 1986 Jul; 47(7):380-2. PubMed ID: 3522559 [Abstract] [Full Text] [Related]
7. Difference in pre- and post-treatment plasma DHEA levels were significantly and positively correlated with difference in pre- and post-treatment Hamilton depression scores following successful therapy for major depression. Hsiao CC. Psychoneuroendocrinology; 2006 Aug; 31(7):839-46. PubMed ID: 16716529 [Abstract] [Full Text] [Related]
8. Risperidone in the treatment of psychotic depression. Goto M, Yoshimura R, Kakihara S, Shinkai K, Yamada Y, Kaji K, Ueda N, Nakamura J. Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110 [Abstract] [Full Text] [Related]
9. Emotional withdrawal, CT abnormalities and drug response in late life depression. Altamura AC, Bassetti R, Santini A, Frisoni GB, Mundo E. Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):349-54. PubMed ID: 14751432 [Abstract] [Full Text] [Related]
10. A longitudinal evaluation of dexamethasone pharmacokinetics in depressed patients and normal controls. Guthrie SK, Heidt M, Pande A, Grunhaus L, Haskett RF, Hariharan M. J Clin Psychopharmacol; 1992 Jun; 12(3):191-6. PubMed ID: 1629386 [Abstract] [Full Text] [Related]
11. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Mao ZL, Stalker D, Keirns J. Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403 [Abstract] [Full Text] [Related]
13. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C. Pharmacopsychiatry; 2003 May; 36(3):98-104. PubMed ID: 12806567 [Abstract] [Full Text] [Related]
14. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Yoshimura R, Nakano Y, Hori H, Ikenouchi A, Ueda N, Nakamura J. Hum Psychopharmacol; 2006 Oct; 21(7):433-8. PubMed ID: 17029305 [Abstract] [Full Text] [Related]
15. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C. Biol Psychiatry; 2007 Jul 01; 62(1):65-71. PubMed ID: 17141744 [Abstract] [Full Text] [Related]
16. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Malhi GS, Ng F, Berk M. Aust N Z J Psychiatry; 2008 Apr 01; 42(4):346-9. PubMed ID: 18330778 [Abstract] [Full Text] [Related]
18. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. Zajecka JM, Jeffries H, Fawcett J. J Clin Psychiatry; 1995 Aug 01; 56(8):338-43. PubMed ID: 7635848 [Abstract] [Full Text] [Related]
19. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Dell'Osso B, Mundo E, D'Urso N, Pozzoli S, Buoli M, Ciabatti M, Rosanova M, Massimini M, Bellina V, Mariotti M, Altamura AC. Bipolar Disord; 2009 Feb 01; 11(1):76-81. PubMed ID: 19133969 [Abstract] [Full Text] [Related]
20. Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Paige SR, Hendricks SE, Fitzpatrick DF, Balogh S, Burke WJ. Psychopharmacol Bull; 1995 Feb 01; 31(2):243-8. PubMed ID: 7491375 [Abstract] [Full Text] [Related] Page: [Next] [New Search]